AGO2 and neoplasm: Therefore, the release of specific miRNAs (e.g., miR-3613-3p) from metastatic tumors in circulation through EVs, facilitated by the increased Ago2/CAV1 interaction in metastatic tumors, can be used as a biomarker of tumor progression (Fig. 10, right panel).